

Method for Expanding and Differentiating Cord Blood Cells

Applications: **Cell therapy.** Facilitate transplantation in situations where a low number of hematopoietic stem cells limits clinical interventions.

Commercial interest: Cellular therapy companies.

Summary: This technology covers a new method of culturing CD34-enriched hematopoietic stem cells from cord blood that leads to **increased yields in total nucleated cells, total myeloid colony-forming cells, megakaryocytic colony-forming cells and platelets**. In addition, this methodology allows to enrich the culture in megakaryocytic progenitors and fully mature megakaryocytes. Furthermore, **a more rapid megakaryocytic maturation** is obtained. Finally, platelet production in 14-day cultures is also several fold higher than standard culture methods.

Intellectual Property: This invention is protected by the following patents: CA 2,562,760, US 7,452,662, and EP 1,743,024. The European patent has been validated in France, Germany, and the United Kingdom.

Assignee: Héma-Québec, Montréal, Québec, CANADA.

Information about this technology, available for licensing, can be obtained from:

Jean-François Leblanc

Scientific Information Specialist

Division of Medical Affairs and Innovation

HÉMA-QUÉBEC

1070, av. des Sciences-de-la-Vie

Quebec City (Quebec), CANADA, G1V 5C3

Tel.: 418 780-4362 ext. 3281, or toll-free (Canada and the U.S.) 1-800-267-9711
ext. 3281

E-mail: Jean-Francois.Lebblanc@hema-quebec.qc.ca